Kybella Consent Form Template for Med Spas (2026)

A drafting template, not legal or clinical advice. This page shows how a Kybella consent document can be organized. It contains no dosing, injection-grid or spacing instructions, prints no session counts, and does not state the law of any state. Kybella is a prescription drug: check every statement on your form against the current FDA prescribing information, and get sign-off from your medical director and a review by healthcare counsel before any patient sees it.

Kybella tends to be added to a menu by practices that already inject neurotoxin and filler, and the consent form is often borrowed from one of those. The borrowed form fails in predictable places. It describes a lunchtime treatment, lists "temporary weakness" without naming the nerve at risk, says nothing about swallowing, and treats the visit as a one-off when the plan is a course.

This page covers that one document. How to run a deoxycholic acid service, from injector training and avoidance-zone mapping to adverse-event management and the session record, is set out in our Kybella compliance guide, and every clinical statement below is limited to what that guide already says. The general law of consent, including capacity, minors and what makes consent valid, sits in our med spa consent forms guide.

Kybella is a trademark of its owner. We use the name because it is how patients ask for the treatment, and we refer to the drug by its generic name, deoxycholic acid, wherever the distinction matters. Nothing here describes or endorses the manufacturer's claims.

What Must a Kybella Consent Form Contain?

A Kybella consent form must name deoxycholic acid and the submental treatment area, disclose any off-label use, explain that fat cells are destroyed and results build over a course of sessions, and have the patient initial the expected swelling. It must name marginal mandibular nerve injury with asymmetric smile, difficulty swallowing and injection-site skin damage, then record screening, alternatives, photo consent, course terms and signatures.

Use the table as an audit of your current form: any row without a matching section is a gap.

Three rows on that table rarely appear on a neurotoxin or filler form in any useful way: the swelling acknowledgment, difficulty swallowing and the course terms. A fourth, nerve injury, appears on many injectable forms only as a vague phrase. Those four rows are where a Kybella form earns its keep, and they get the most attention below.

Why a Toxin or Filler Form Will Not Stretch to Cover Kybella

Our Botox consent form guide and dermal filler consent form template describe forms built around a product that relaxes a muscle or occupies space. Deoxycholic acid does neither: our compliance guide explains that it destroys fat cells, that destroyed cells cannot store fat again, and that the drug does not distinguish fat from other tissue if it is placed in the wrong spot. A Kybella form therefore has to say that the intended effect is lasting, that the recovery is meant to look dramatic, and that the serious risk sits on one named nerve under the jawline. Toxin wording about effects "wearing off" or filler wording organized around vascular events tells the patient something untrue or incomplete about this treatment.

The Annotated Kybella Consent Template

The layout below runs in the order a patient should meet the information: what is being done, what it will feel and look like, what can go wrong, what else they could do, and what they are signing. Each section carries two notes. Records says what the section has to capture. Watch for names the drafting error that most often weakens it. The wording is yours to write with your medical director; counsel then checks it against your state's requirements.

Section 1 — Identification and form version

Records: patient name, date of birth, visit date, chart reference, and the version number and effective date of the template. Watch for: a form with no version number. A course of sessions can stretch across a template revision, and without a version you cannot show which wording the patient signed at the start and which they confirmed later.

Section 2 — Procedure description

Records: the drug named as deoxycholic acid (with the brand if that is the product used), the area to be treated, and a plain statement of the approved use. Our compliance guide summarizes the FDA approval as covering the improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults, and notes that the prescribing information states safe and effective use outside the submental region has not been established and is not recommended. If your medical director authorizes any other site, the form names that site and says the use is off-label. Watch for: "fat reduction injection" with no drug or area named, or an off-label site added in the chart but never on the form.

Section 3 — How the treatment works and the expected course

Records: two or three sentences explaining that the drug destroys fat cells under the chin, that the body clears them gradually, that improvement appears over time rather than on the day, and that a course of more than one session is usually planned, with the number decided by the treating practitioner for the individual patient. It should say plainly that the final result can only be judged once the course is complete. Watch for: a session count or a timeline printed in this section. Our compliance guide summarizes what the labeling permits on sessions and spacing; that belongs in your SOP and the treatment plan, not in patient-facing wording that will be read as a promise.

Section 4 — Swelling and recovery acknowledgment

Records: a short, boxed statement that the area under the chin is expected to swell markedly after each session, possibly enough to look obviously enlarged; that the first session is often the most noticeable; that bruising, tenderness, numbness and firmness or small lumps under the chin commonly come with it and may persist for some time; and that this is the expected response rather than a complication. Ask the patient to initial it. Watch for: softening this into "some patients experience mild swelling." That sentence is what turns an expected recovery into a complaint.

Section 5 — Common reactions

Records: the expected, usually short-lived reactions our compliance guide lists: swelling, bruising, pain, numbness, redness and areas of firmness or nodules under the chin. Watch for: mixing these into the serious-risk list. When a nerve injury sits in the same sentence as bruising, neither reads correctly.

Section 6 — Serious risks

Records: each of the following on its own line, in plain language: injury to the marginal mandibular nerve, which can cause an uneven or asymmetric smile or weakness of the lower face; difficulty swallowing, which can occur particularly while the area is swollen; and injection-site injury, including tissue damage and, rarely, skin ulceration or necrosis. Your medical director may add others from the current prescribing information. Watch for: qualifiers such as "very rare" or "almost always temporary" attached to the nerve line. The later sections on nerve and swallowing wording explain why.

Section 7 — Health history and screening confirmation

Records: the patient's confirmation that the answers they gave on the screening questions are complete and true, and an undertaking to report any change before each later session. Watch for: a confirmation line with no screening questions behind it. The questions themselves are covered in the screening section below.

Section 8 — Alternatives

Records: that other approaches to the area were discussed, and that declining treatment is an option. Watch for: a single word, "alternatives," with a tick box beside it. Name the options in general terms so the patient can recognize what was discussed.

Section 9 — Photography

Records: consent to clinical photographs for the record, with marketing use requested separately. Watch for: a marketing release folded into the clinical line. Detail follows below.

Section 10 — Course and financial terms

Records: whether the patient is buying one session or a planned course, and that payment does not guarantee a result. Watch for: package wording that pairs a fixed number of sessions with a fixed outcome.

Section 11 — Aftercare, warning signs and after-hours contact

Records: receipt of written aftercare, the symptoms that need an urgent call, and an after-hours route. Watch for: warning signs that appear only on the handout and not on the signed form.

Section 12 — Attestation, signatures and session confirmations

Records: the patient's own first-person statement that they have read the document, raised any questions, received answers and choose to go ahead; the patient's dated signature; the consenting clinician's name, credential and signature and, if different, the treating injector's; and a confirmation grid for later sessions. Watch for: a single signature meant to cover the whole course with no record of what was checked at each visit.

Writing the Swelling Acknowledgment So It Holds Up

Our compliance guide describes the swelling after deoxycholic acid as the single most important thing a Kybella patient must understand before treatment, and patients describe it in vivid terms. The acknowledgment has one job: to let you show, later, that the patient was told what they would look like and accepted it.

Describe the appearance, not just the symptom

"Swelling" is a word patients have heard on every consent form they have ever signed. What they have not heard is that they may look as if they have a pouch under the jaw, that it can be obvious to colleagues and family, and that it may affect plans such as work presentations or events. Say it in that kind of language. Our compliance guide also notes that the first session is often the most pronounced; putting that on the form prevents the patient who sails through a later session from concluding that the first one went wrong, and the reverse.

Keep the duration qualitative

Our compliance guide gives a general range for how long swelling can last. The form is a poor place for it. A range on a signed document reads as a guarantee, and the patient whose swelling outlasts it has a printed basis for a complaint. Describe the course in words such as "usually settles over the following days to weeks" only if your medical director is comfortable with that phrasing, and let the clinician explain the expected pattern for that patient in the room. Record in the chart that the conversation happened.

Place the acknowledgment in an initialled box before the serious-risk section, so the patient reads what normal recovery looks like before reading what is not normal, and your phone staff can point back to a box the patient signed.

Wording the Nerve-Injury and Asymmetric-Smile Disclosure

This is the line a complaint will turn on. Our compliance guide describes marginal mandibular nerve injury as the defining risk of the treatment, and notes that a nerve-injury complaint usually comes down to two records: the consent that disclosed it and the documentation that the injector respected the avoidance zone. The form is the first of those.

Name it and describe what the patient would see

Patients do not know what the marginal mandibular nerve is. Name it once for the record, then describe the effect in terms they will recognize: the smile may become uneven or lopsided, one side of the lower lip may not move normally, and the lower face may feel weak. A patient who notices a crooked smile and finds those words on their own form recognizes the event they were warned about.

Report the course without promising it

Our compliance guide reports that in the clinical trials all reported cases resolved without treatment, over a period ranging from days to many months, and also notes that the literature describes nerve effects that occasionally persist. The form can say the effect is usually temporary, that recovery time varies widely, and that resolution cannot be guaranteed. What the form should not do is lead with reassurance. "Rare and always temporary" is not what the evidence on our own page says, and it is the phrase that will be read back to you.

Keep the form patient-facing: it is enough to say that the practitioner marks and avoids a zone near the jawline under the practice's written protocol. The detail of that protocol, and the record showing it was followed, belong in the SOP and the treatment note.

Disclosing Difficulty Swallowing Without Overstating It

Our compliance guide lists difficulty swallowing among the serious risks, notes that it can occur particularly in the context of swelling, and treats it as a symptom that requires urgent assessment rather than reassurance. The form should mirror that, and go no further.

In practice, that means a plain line in the serious-risk section saying that difficulty swallowing can occur, especially while the area is swollen; a matching line in the warning-signs section telling the patient to contact the practice at once if swallowing becomes difficult; and a screening question asking whether the patient has ever had trouble swallowing. Leave mechanism, severity and management to the medical director's protocol.

The disclosure draws a boundary: tightness and swelling under the chin are expected; difficulty swallowing is not, and means calling at once.

Contraindication and Candidacy Screening for Kybella

Screening is where the form connects to the good-faith examination. The patient answers questions; the examining clinician reviews the answers and decides whether to proceed. The consent form then records that the patient confirmed their answers were complete.

Screening questions drawn from our compliance guide

Our Kybella compliance guide names the factors that change risk. Each one should appear as a direct question on the intake or screening page that accompanies the form:

• Any infection, sore or skin problem in the area under the chin.
• Any previous surgery, procedure or anatomical change in the neck or chin area.
• Any current or past difficulty swallowing.
• Any bleeding disorder, or use of blood-thinning medicines.
• Whether the patient is pregnant, may be pregnant or is breastfeeding.
• Any other condition or medicine your medical director's protocol flags.

Keep those questions on the screening page, where they can be updated with the protocol. Build the wider health history using our guide to med spa intake forms.

Candidacy belongs in the practitioner's note

Our compliance guide explains that the best candidate has a discrete pad of fat under the chin, and that fullness driven mainly by loose skin, prominent neck bands or an underlying anatomical issue makes disappointment more likely, since destroying fat will not tighten skin and can make laxity more visible. The form can carry a short practitioner field confirming that candidacy was assessed, that the patient was told the treatment will not tighten skin, and, where relevant, that a different option was discussed instead.

Alternatives the Patient Should See Named

An alternatives line protects the practice only if it shows that real options were put to the patient. For submental fullness, the form can list them in general terms without arguing for or against any:

• Other non-surgical approaches the practice or others offer for the area, named generically rather than by brand.
• Surgical options, with a note that the patient can be referred for a surgical opinion.
• No treatment, stated as a reasonable choice.

Photo Consent for a Result That Arrives Slowly

Our compliance guide recommends standardized pre-treatment photographs with consistent angles, lighting and framing, under separate photography consent, because they provide the baseline that shows the change once the course is complete. Kybella makes this especially important: the result emerges gradually, swelling obscures it between sessions, and a patient's memory of their starting point fades.

The clinical consent should cover the chin, jawline and neck before the first session, at later visits and whenever a possible adverse event is reported, since a same-day picture of an uneven smile or skin change belongs in the incident record.

Marketing use is a separate decision, recorded on a separate line or document, revocable, and never a condition of treatment. Before-and-after images of a submental result raise their own advertising questions; our guide to FTC before-and-after photo rules covers them.

Course, Package and Financial Terms

Our compliance guide calls the "I wasn't told it would take this long" complaint among the most common in submental fat treatment. Written terms address both the expectation and the money.

What the terms should say

• Whether the patient is paying for one session or a planned course, and that the number of sessions is decided by the practitioner as the course progresses.
• That a course does not guarantee a particular result.
• What happens to prepaid sessions if the patient stops, if the clinician judges that continuing would be inappropriate, or if a complication pauses the course.
• Any time limits on using prepaid sessions, and any refund or transfer policy.

Prepayment, refunds and packages are governed by contract and consumer law that differs between states, so have counsel sign off on the wording. Some practices keep the full terms in a standalone course agreement that the consent refers to.

Never let payment come first

Take payment for a course only after the consent discussion. A patient who has already paid may feel bound to go ahead after hearing about nerve injury or swallowing difficulty, and a reviewer will read prepayment before consent as pressure. Keep the financial section out of the risk section entirely.

Signatures and Per-Session Confirmation

Our compliance guide treats each session as generating its own record, and the consent should follow the same rhythm. The first signature covers the course as explained; each later session needs a short confirmation that nothing material has changed.

The initial signature block

The patient's attestation and dated signature; the consenting clinician's name, credential and signature; the treating injector if different; a witness line if your policy requires one, and the form version. Patients should sign before any marking or preparation begins, with time to read the form and an invitation to ask questions recorded in the chart.

The session confirmation table

Add a confirmation grid as the last page. Each row records the session date, any change in health history or medicines since the last visit, whether the patient experienced any of the listed serious effects after the previous session, confirmation that the swelling acknowledgment was revisited, and initials from both patient and clinician. A recorded nerve or swallowing symptom triggers review under your protocol before treatment continues. Material changes, such as a new treatment site or a revised form, call for a fresh full consent rather than a row in the table.

Who Should Obtain Kybella Consent?

The consent discussion belongs to a clinician who can answer questions about the drug, the nerve risk and the recovery: the injector who will treat, or the practitioner whose examination led to the treatment order. A coordinator can hand over the form but should not explain the risks, and the form should name the clinician who did. Our guide to medical director requirements explains the oversight role that sits behind the form.

Who may lawfully examine, order and inject deoxycholic acid depends on the state, the license held, and the supervision and delegation rules that apply, and no single national rule exists; this page leaves that question to your state's law. Our overview of who can inject across the United States explains how those rules vary; confirm the position in your state with counsel before deciding who signs the practitioner line.

Warning Signs the Form Should Print

The warning-signs section is where expected recovery and a reportable event part company. Our compliance guide draws the line clearly, and the form can follow it almost word for word in patient language.

• Expected: swelling, bruising, numbness, firmness and tenderness under the chin.
• Call the practice: an uneven smile or weakness of the lower face or lip.
• Call at once: any difficulty swallowing.
• Call the practice: skin breakdown, an open sore, or an injection site that does not heal.

Give an after-hours route that is actually answered, and tell the patient what to do if they cannot reach anyone and feel unwell. Do not describe how the practice will treat any of these events; say only that the practice has a written plan and will assess the patient. Our emergency protocol guide covers the practice side.

Common Kybella Consent Mistakes

Most weak Kybella forms are weak in the same ways. Each of these is avoidable at the drafting stage.

A general "injectables" form with Kybella added to the list

The nerve, swallowing and swelling disclosures are missing or buried among toxin and filler risks. A deoxycholic acid patient needs a document written for that treatment.

Swelling described as mild

Understating the expected recovery is the most common Kybella consent error and the easiest to fix. If the patient's photographs after a session show far more swelling than the form described, the form becomes the complainant's exhibit.

"Temporary weakness" instead of a named nerve risk

Generic wording does not establish informed consent for a specific risk. Our compliance guide makes the same point: the named nerve risk is the one a complaint centers on.

A session count or timeline printed for the patient

Patients treat any number they signed as a commitment. Keep them in the SOP and the practitioner's plan.

An off-label site treated on an on-label form

If any area other than the submental region is treated, the form must say so and say that the use is off-label, as our compliance guide requires.

Marking before consent

If the avoidance zone and treatment area are marked before the form is signed, the timeline suggests the decision was made for the patient. Sign first, then mark.

Record Retention for Kybella Consent

A signed Kybella consent, its session confirmations, the screening answers and the photographs are part of the medical record. Retain them on the same schedule as the patient's chart; that schedule comes from state law and other obligations, which vary. There is no separate Kybella rule; apply your practice's records policy, confirmed by counsel. Our guide to medical records and retention covers the general framework.

Keep every document for a course together so it can be produced as one file, and keep every superseded version of the template, because a dispute asks what the form said on the day it was signed.

Keeping the Form in Step With Your Kybella SOP

The form describes risks your SOP manages, so read the two side by side whenever either changes, or the prescribing information does. Every event in the adverse-event protocol should appear on the form, every screening question should match a factor the SOP treats as relevant, and the form should promise nothing the practice does not provide. Log each review against the template's version history, even when nothing changes.

Key Takeaways

• Write a Kybella-specific form naming deoxycholic acid and the submental area, and mark any other site as off-label.
• Describe the course and the gradual result in words; print no session counts or timelines.
• Put the expected swelling in an initialled box, and describe how the patient will look.
• Name marginal mandibular nerve injury and the uneven smile without promising resolution, and make difficulty swallowing an urgent warning sign.
• Back the screening confirmation with real questions and record candidacy in a practitioner field.
• Keep marketing photos and payment terms apart from the clinical consent, and confirm consent at every session.
• Your medical director and counsel approve the final wording.

This page describes one way to organize a Kybella consent document. It is not clinical or legal advice and does not state the law of any jurisdiction. Kybella is a trademark of its owner, named for identification only. Your medical director and a healthcare attorney should approve the final form against the current prescribing information and the rules that apply to your practice.